Table 1 Cox regression analysis of treatment-free survival in the whole cohort
|  |  | Univariable |  | Multivariable (n = 365) | |
|---|---|---|---|---|---|
N pts analyzed | HR (95% CI) | p-value | HR (95% CI) | p-value | |
male gender | 442 | 0.97 (0.76–1.22) | 0.8 | − | − |
age ≥ 65 | 441 | 0.97 (0.77–1.23) | 0.8 | − | − |
Rai stage II–III–IV | 434 | 2.60 (2.03–3.32) | <0.0001 | 2.59 (1.98–3.41) | <0.0001 |
CD49d positive (≥30%) | 440 | 1.48 (1.13–1.92) | 0.004 | 1.65 (1.22–2.23) | 0.001 |
CD38 positive (≥30%) | 439 | 1.13 (0.89–1.43) | 0.3 | − | − |
ZAP-70 positive (≥20%) | 389 | 1.44 (1.11–1.87) | 0.005 | n.i. | n.i. |
IGHV unmutated | 428 | 2.16 (1.66–2.8) | <0.0001 | 1.83 (1.37–2.45) | <0.0001 |
TP53 disrupted (del17p and/or TP53 mutated) | 442 | 1.70 (1.24–2.32) | 0.0008 | 1.46 (1.05–2.03) | 0.024 |
NOTCH1 mutated | 442 | 1.37 (1.08–1.73) | 0.009 | n.i. | n.i. |
SF3B1 mutated | 327 | 1.46 (0.90–2.38) | 0.1 | − | − |
BIRC3 mutated | 343 | 0.93 (0.65–1.34) | 0.7 | − | − |
KRAS mutated | 442 | 1.49 (0.96–2.30) | 0.073 | − | − |
NRAS mutated | 442 | 1.86 (0.99–3.50) | 0.055 | − | − |
BRAF mutated | 442 | 1.34 (0.75–2.40) | 0.3 | − | − |
KRAS/NRAS mutated | 442 | 1.54 (1.05–2.25) | 0.025 | 1.56 (1.04–2.36) | 0.033 |
